NewTimeSpace News: Jiangsu Hengrui Pharmaceuticals Co., Ltd. (01276.HK) announced that its subsidiaries have received the Drug Clinical Trial Approval Notice ratified and issued by NMPA. Phase II clinical trials are approved to evaluate SHR‑A2009 for Injection (HER3‑targeted ADC) in combination with adebrelimab, or in combination with third‑generation EGFR TKI, among patients with non‑small‑cell lung cancer. To date, no HER3‑targeted ADC has been approved globally for the treatment of NSCLC.
NewTimeSpace News: CSPC Pharmaceutical Group Limited (01093.HK) announced that the New Drug Application for neoadjuvant therapy of Anitumab (KN026) co‑developed with Alphamab Oncology in combination with the Group’s self‑developed Docetaxel (Albumin‑Bound) for Injection (HB1801) for adult patients with early or locally advanced HER2‑positive breast cancer has been accepted by NMPA and included in the priority review and approval procedure. A pivotal Phase III study demonstrated that the combination regimen significantly improved the overall pathological complete response rate versus current standard‑of‑care treatment.
On August 4, 2026, Hong Kong's three major indices traded in a mixed session with divergent outcomes. The Hang Seng Index fell 0.60%, while the Hang Seng Tech Index rose 0.21%, and the Hang Seng China Enterprises Index declined 0.90%. Total turnover on the Hang Seng Index reached HKD 257.8 billion.The AI chip and hardware segment staged a broad-based rebound, catalyzed by the open‑sourcing of MiniMax H3, which triggered a "Day 0 adaptation" wave among domestic GPU manufacturers. Tianshu Zhixin surged over 11%, GigaDevice gained more than 8%, Biren Technology advanced nearly 7%, while Hua Hong Semiconductor, Montage Technology, SMIC, and other related names all closed higher.
NewTimeSpace News: Fujian Haixi Pharmaceuticals Co., Ltd. (02637.HK) announced that its self‑developed candidate HX9428 has obtained US‑FDA IND clearance to commence Phase II clinical trial for neovascular age‑related macular degeneration (nAMD). Meanwhile, the Company has officially launched its second Phase II clinical study (CTR20262884) of HX9428 for nAMD in China, adopting a head‑to‑head positive‑control design against aflibercept.
NewTimeSpace News: Sino Biopharmaceutical Limited (01177.HK) announced that the New Drug Application (NDA) for TQB3909 Tablets, a Class‑1 innovative BCL‑2 inhibitor independently developed by its subsidiary Chia‑Tai Tianqing, has been accepted by CDE under NMPA. The drug is indicated for adult patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) who have received at least one prior systemic therapy including a BTK inhibitor. The candidate was granted priority review status in July 2026.
NewTimeSpace News: On August 4, 2026, XPENG-W (09868.HK) fluctuated downward in the afternoon session. As at 15:23, the stock was quoted at HK$46.72, down 4.73%. XPeng delivered 38,027 new vehicles in July, representing a 4% year-on-year increase.
NewTimeSpace (newtimespace.com) reported that on August 4, 2026, the chip theme strengthened, with ASMPT (00522.HK) fluctuating higher. As of 13:24, the stock was quoted at HKD 156.300, up 3.99%.
NewTimeSpace (newtimespace.com) reported that on August 4, 2026, the robotics theme continued to strengthen, while Xiaomi-W (01810.HK) fluctuated lower. As of 13:17, the stock was quoted at HKD 27.600, down 1.29%.
NewTimeSpace News: CARsgen Therapeutics announced on August 4 that CT0596, the Company’s allogeneic CAR-T cell product targeting BCMA, has obtained IND approval from the NMPA for the treatment of patients with relapsed/refractory multiple myeloma.
NewTimeSpace News: Shaanxi Micot Pharmaceutical Technology announced on August 3 that the Phase II clinical trial of its self-developed candidate drug MT200605 for the treatment of acute ischemic stroke has achieved the primary efficacy endpoint.
NewTimeSpace News: Alphamab Oncology (09966.HK) announced that JSKN033, a high-concentration subcutaneous fixed-dose combination consisting of HER2 bispecific ADC and PD-L1 immune checkpoint inhibitor, has obtained approval from CDE of NMPA to initiate a Phase III clinical study (Trial No. JSKN033-301) as monotherapy for recurrent or metastatic cervical cancer refractory to platinum-based chemotherapy and PD-1/PD-L1 inhibitors. JSKN033 is the world’s first such high-concentration subcutaneous injectable combination product.
NewTimeSpace News: CSPC Pharmaceutical Group Limited (01093.HK) announced that the Phase Ib/II clinical trial (SYS6090-008) evaluating the combination therapy of SYS6090 Injection for colorectal cancer developed by the Group has officially been initiated at the first study centre in China. The product is a recombinant fully human anti-PD-1 fusion protein fused with IL-15, classified as Class 1 therapeutic biological product.
NewTimeSpace News: Ascletis Pharma Inc. (01672.HK) announced that once-daily oral small-molecule GLP-1 ASC30 has obtained FDA clearance to initiate global Phase III clinical studies. Two pivotal trials will be conducted in the United States, Europe and Canada, enrolling approximately 4,600 obese or overweight subjects. Meanwhile, the Company disclosed first-in-class oral small-molecule GLP-1/GIP/amylin triple-target fixed-dose combination (FDC) achieved up to 15.2% weight loss in non-human primates, representing a relative improvement of 120% compared with the dual-target formulation.
NewTimeSpace News: SH PHARMA (02607.HK) announced that its subsidiary SPH Xinyi has obtained the Drug Registration Certificate for Omeprazole Sodium Bicarbonate for Oral Suspension (I) issued by the National Medical Products Administration, and the drug is approved for production. Each sachet contains 20mg Omeprazole and 1680mg Sodium Bicarbonate. Classified as Class 3 Chemical Drug, it is mainly indicated for short-term treatment of active duodenal ulcer and gastroesophageal reflux disease.
NewTimeSpace News: Fusen Pharmaceutical Company Limited (01652.HK) announced that four of the Group’s products have been proposed to win the bid in the tender of China’s 12th National Centralized Drug Procurement, namely Nicardipine Injection, Azilsartan Potassium Tablets, Potassium Hydrogen Phosphate Compound Injection and Dydrogesterone Tablets.
On August 3, 2026, Hong Kong's three major indices rallied in volatile trading. The Hang Seng Index rose 0.48%, the Hang Seng Tech Index gained 0.96%, and the Hang Seng China Enterprises Index advanced 0.46%.AI concept stocks showed mixed performance. Alibaba-W (09988.HK) and MINIMAX-W (00100.HK) surged over 7% on the back of new model releases, while Zhipu (02513.HK) fell nearly 5%, highlighting a clear divergence within the large-model sector.
